gusacitinib   Click here for help

GtoPdb Ligand ID: 10000

Synonyms: ASN-002 | ASN002 | example 189 [WO2013028818A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Gusacitinib (ASN002) is an orally bioavailable dual spleen tyrosine kinase (SYK)/pan Janus kinase (JAK) inhibitor that is being developed by Asana BioSciences. It is being evaluated for clinical efficacy in inflammatory and oncology settings. Not to be confused with Ascend Biopharmaceuticals immuno-oncology lead ASN-002, which is an engineered virus that expresses IFN-γ.
Gusacitinib is one of the chemical structures (example 189) claimed in Asana Biosciences' patent WO2013028818A1 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 134.06
Molecular weight 460.23
XLogP 2.6
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#CCC1CCN(CC1)c1nc(Nc2ccc(cc2)N2CCC(CC2)O)c2c(n1)cn[nH]c2=O
Isomeric SMILES N#CCC1CCN(CC1)c1nc(Nc2ccc(cc2)N2CCC(CC2)O)c2c(n1)cn[nH]c2=O
InChI InChI=1S/C24H28N8O2/c25-10-5-16-6-11-32(12-7-16)24-28-20-15-26-30-23(34)21(20)22(29-24)27-17-1-3-18(4-2-17)31-13-8-19(33)9-14-31/h1-4,15-16,19,33H,5-9,11-14H2,(H,30,34)(H,27,28,29)
Immunopharmacology Comments
ASN002 simultaneously inhibits two signalling pathways that impinge on the inflammatory response. This dual action is predicted to provide improved clinical efficacy. ASN002 has completed a Phase 2 evaluation in patients with atopic dermatitis (NCT03139981).